FDA to Revisit Opioid Labeling for Chronic Pain
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures
DALLAS, July 24, 2025 (GLOBE NEWSWIRE) — Upsize Clinic, a leading provider of non-surgical male enhancement treatments, announces the opening of its newest clinic location in Dallas at 5232 Forest Lane, Suite 170. The clinic, led by board-certified physician Dr. Brad Sellers, offers the company's proprietary Upsize™ and Firm-X™ procedures, providing men in the Dallas-Fort Worth metroplex access to clinically proven, minimally invasive male enhancement procedures. The new Dallas location represents Upsize's continued national expansion, following the company's recent milestone of surpassing 1,500 successful procedures across its network of 20 affiliated physicians nationwide. The clinic specializes in two groundbreaking treatments: the Upsize™ procedure utilizing hyaluronic acid dermal fillers for girth enhancement, and the Firm-X™ treatment employing neuromodulator injections for improved function and appearance. 'Dallas men now have access to safe, effective enhancement options that deliver immediate results without the risks and downtime associated with surgical procedures,' said Dr. Brad Sellers, Medical Director of Upsize Dallas. 'These innovative treatments represent a significant advancement in male aesthetic medicine, offering natural-looking results that boost confidence and improve quality of life.' About Dr. Brad Sellers Dr. Sellers brings over two decades of medical expertise to his practice, having served as Medical Director and Associate Medical Director at several prominent Dallas-area Emergency Departments and Level 1 and Level 2 Trauma Centers. His extensive background in emergency medicine, combined with his Certified Physician Executive credentials from the American Association of Physician Leaders, ensures the highest standards of patient safety and care. Recently completing specialized training in male enhancement procedures through Upsize LLC, as well as neurotoxin and dermal filler certification from the National Laser Institute, Dr. Sellers has expanded his practice to focus on intimate wellness and aesthetic treatments for men. His commitment to excellence and patient-centered approach makes him uniquely qualified to deliver these innovative procedures. The Upsize™ Procedure: Non-Surgical Girth Enhancement The flagship Upsize™ procedure uses FDA-approved hyaluronic acid dermal fillers (used off-label) administered via micro-cannula to achieve natural girth enlargement and improved symmetry. Key benefits include: Immediate Results : Patients see enhancement immediately following the 30-minute in-office procedure : Patients see enhancement immediately following the 30-minute in-office procedure Minimal Downtime : Most men return to normal activities within days : Most men return to normal activities within days Reversible Option : Results can be adjusted or reversed if desired : Results can be adjusted or reversed if desired Natural Feel : Maintains natural texture and sensation : Maintains natural texture and sensation Long-Lasting: Results typically last an average of 24 months Firm-X™: Revolutionary Neuromodulator Treatment The innovative Firm-X™ treatment utilizes neurotoxin injections to enhance male sexual health and appearance. This procedure works by relaxing smooth muscles in corpus cavernosum vasculature, leading to: Enhanced blood flow and circulation Reduced retraction for a fuller appearance Improvements in erectile dysfunction The treatment involves strategic placement of 100 units of neuromodulator through four injection points, with the entire procedure completed in under 30 minutes. Meeting Growing Demand for Male Enhancement The opening of Upsize Dallas addresses increasing demand for physician administered male aesthetic treatments in North Texas. As men become more comfortable seeking enhancement options, the need for safe, effective alternatives to risky surgeries and unregulated products has grown significantly. 'Men seeking enhancement deserve access to clinically proven treatments performed by qualified medical doctors,' Dr. Sellers noted. 'Our procedures offer a discreet, professional solution that prioritizes both results and safety.' Comprehensive Patient Care The Dallas clinic provides confidential consultations where patients can discuss their options and determine the most appropriate treatment plan. Both procedures are performed in a discrete, medical-grade facility with strict adherence to safety protocols. Patients receive lifetime follow-up care at no additional charge, ensuring ongoing support and satisfaction. About Upsize LLC Headquartered in Roseville, California, Upsize LLC specializes in minimally invasive male enhancement treatments. The company's proprietary procedures have earned recognition for their safety profile, immediate results, and high patient satisfaction rates. With locations across California, Texas, Florida, New York, New Jersey, Ohio, Arizona, Nebraska, and international expansion into Panama and Canada, Upsize continues to lead innovation in male aesthetic medicine. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Bloomberg
2 hours ago
- Bloomberg
UnitedHealth is Responding to Civil, Criminal DOJ Probes
UnitedHealth Group Inc. is responding to criminal and civil requests from the US Department of Justice about its Medicare practices, the company said, confirming reports of probes that have added to mounting challenges for the largest US health insurer. Bloomberg's John Tozzi reports. (Source: Bloomberg)
Associated Press
2 hours ago
- Associated Press
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release
